Abstract
Parkinson’s disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Although the exact cause of the dopaminergic neurodegeneration remains elusive, recent postmortem and experimental studies have revealed a crucial role of neuroinflammation that is initiated and driven by activated microglial cells and their neurotoxic products during PD pathogenesis. Inflammatory responses manifested by glial reactions are currently recognized as one of the prominent features of PD. Indeed, activated microglial cells have been detected in the SNpc of patients with PD. Postmortem analysis and preclinical investigations conducted in various animal models exposed to neurotoxins have also revealed dramatic and massive astrogliosis with the presence of activated microglial cells in the SNpc. Although a number of neurotoxic, pharmacologic, and transgenic animal models are available for mechanistic and drug discovery studies in PD, selection and use of a good experimental PD model has always been a challenge. Significant advances in modeling neuroinflammatory features and expansion to new species have occurred to better characterize the pathological mechanisms in PD. Here, we outline the remarkable array of animal and cellular neuroinflammatory models available, with particular emphasis on their benefits and pitfalls and the contribution each has made to delineate the neuroinflammatory mechanisms underlying PD. This review suggests that further investigation concerning use of optimal neuroinflammatory experimental PD models might help to identify disease-modifying therapeutic approaches in future drug discovery and may shed light on understanding PD pathogenesis.
Keywords: Experimental models, microglia, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, neurodegeneration, neuroinflammation, Parkinson’s disease.
CNS & Neurological Disorders - Drug Targets
Title:Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies
Volume: 12 Issue: 5
Author(s): Sandeep Vasant More, Hemant Kumar, In-Su Kim, Sushruta Koppulla, Byung-Wook Kim and Dong-Kug Choi
Affiliation:
Keywords: Experimental models, microglia, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, neurodegeneration, neuroinflammation, Parkinson’s disease.
Abstract: Parkinson’s disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Although the exact cause of the dopaminergic neurodegeneration remains elusive, recent postmortem and experimental studies have revealed a crucial role of neuroinflammation that is initiated and driven by activated microglial cells and their neurotoxic products during PD pathogenesis. Inflammatory responses manifested by glial reactions are currently recognized as one of the prominent features of PD. Indeed, activated microglial cells have been detected in the SNpc of patients with PD. Postmortem analysis and preclinical investigations conducted in various animal models exposed to neurotoxins have also revealed dramatic and massive astrogliosis with the presence of activated microglial cells in the SNpc. Although a number of neurotoxic, pharmacologic, and transgenic animal models are available for mechanistic and drug discovery studies in PD, selection and use of a good experimental PD model has always been a challenge. Significant advances in modeling neuroinflammatory features and expansion to new species have occurred to better characterize the pathological mechanisms in PD. Here, we outline the remarkable array of animal and cellular neuroinflammatory models available, with particular emphasis on their benefits and pitfalls and the contribution each has made to delineate the neuroinflammatory mechanisms underlying PD. This review suggests that further investigation concerning use of optimal neuroinflammatory experimental PD models might help to identify disease-modifying therapeutic approaches in future drug discovery and may shed light on understanding PD pathogenesis.
Export Options
About this article
Cite this article as:
More Vasant Sandeep, Kumar Hemant, Kim In-Su, Koppulla Sushruta, Kim Byung-Wook and Choi Dong-Kug, Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/18715273113129990059
DOI https://dx.doi.org/10.2174/18715273113129990059 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Dengue Virus Entry/Fusion Inhibition By Small Bioactive Molecules: A Critical Review
Mini-Reviews in Medicinal Chemistry Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Association between <i>Toxoplasma gondii</i> Infection and Headache: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Combat Military Personnel and Selective Risk Factors for the Development of Dementias - A Review
Current Psychiatry Research and Reviews Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism